X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32) 32
index medicus (32) 32
oncology (32) 32
male (25) 25
adult (24) 24
female (24) 24
middle aged (24) 24
surgery (22) 22
melanoma (20) 20
sarcoma (19) 19
aged (18) 18
medicine & public health (17) 17
prognosis (15) 15
surgical oncology (14) 14
analysis (12) 12
cancer (12) 12
adolescent (11) 11
aged, 80 and over (11) 11
survival (10) 10
survival rate (10) 10
metastasis (9) 9
young adult (9) 9
disease-free survival (8) 8
follow-up studies (8) 8
recurrence (8) 8
risk factors (8) 8
tumors (8) 8
care and treatment (7) 7
chemotherapy (7) 7
gastrointestinal stromal tumors - drug therapy (7) 7
mutation (7) 7
neoplasm staging (7) 7
treatment outcome (7) 7
hematology, oncology and palliative medicine (6) 6
imatinib mesylate (6) 6
melanoma - pathology (6) 6
multivariate analysis (6) 6
neoplasm recurrence, local - pathology (6) 6
patient outcomes (6) 6
retrospective studies (6) 6
antineoplastic agents - therapeutic use (5) 5
biomarkers, tumor - genetics (5) 5
gastrointestinal stromal tumors - pathology (5) 5
lymph node excision (5) 5
lymphatic metastasis (5) 5
melanoma - genetics (5) 5
melanoma - mortality (5) 5
nivolumab (5) 5
protein kinase inhibitors - therapeutic use (5) 5
term-follow-up (5) 5
advanced melanoma (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cancer therapies (4) 4
child (4) 4
drug therapy (4) 4
ipilimumab (4) 4
kaplan-meier estimate (4) 4
management (4) 4
medical colleges (4) 4
melanoma - drug therapy (4) 4
melanoma - surgery (4) 4
mesylate (4) 4
neoplasm recurrence, local - mortality (4) 4
piperazines - therapeutic use (4) 4
prognostic-factors (4) 4
pyrimidines - therapeutic use (4) 4
soft-tissue sarcoma (4) 4
abridged index medicus (3) 3
adjuvant imatinib (3) 3
american joint committee (3) 3
benzamides (3) 3
benzamides - therapeutic use (3) 3
biopsy (3) 3
clinical trials (3) 3
cohort studies (3) 3
combined modality therapy (3) 3
cutaneous melanoma (3) 3
development and progression (3) 3
dissection (3) 3
early-stage melanoma (3) 3
experience (3) 3
follow-up (3) 3
gastrointestinal neoplasms - drug therapy (3) 3
gastrointestinal stromal tumor (3) 3
gastrointestinal stromal tumors - genetics (3) 3
gastrointestinal stromal tumors - mortality (3) 3
gastrointestinal stromal tumors - secondary (3) 3
hematology (3) 3
high-risk (3) 3
imatinib (3) 3
kit (3) 3
lymphadenectomy (3) 3
malignant-melanoma (3) 3
medical research (3) 3
medicine/public health, general (3) 3
melanoma - secondary (3) 3
optics (3) 3
pembrolizumab (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 2016, Volume 42, Issue 12, pp. 1906 - 1913
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2019, Volume 20, Issue 8, pp. 1148 - 1159
SummaryBackgroundPathological complete response to preoperative treatment in adults with soft-tissue sarcoma can be achieved in only a few patients receiving... 
Hematology, Oncology, and Palliative Medicine | INDUCED PATHOLOGICAL NECROSIS | NEOADJUVANT CHEMOTHERAPY | HIGH-GRADE | ONCOLOGY | EUROPEAN ORGANIZATION | HIGH-RISK | POSTOPERATIVE RADIOTHERAPY | EXTREMITY | RECURRENCE | RADIATION-THERAPY | Care and treatment | Sarcoma | Radiotherapy | Analysis | Hafnium | Index Medicus
Journal Article
Annals of surgical oncology, ISSN 1068-9265, 08/2019
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 7/2019, Volume 26, Issue 7, pp. 2304 - 2305
Journal Article
Physical Review A - Atomic, Molecular, and Optical Physics, ISSN 1050-2947, 01/2015, Volume 91, Issue 1
We present a construction of quantum states in dimension d that has at least 1 dit of ideal key, called private dits (pdits), which covers most of the known... 
BOUND ENTANGLEMENT | OPTICS | KEY | PHYSICS, ATOMIC, MOLECULAR & CHEMICAL | Physics - Quantum Physics
Journal Article
Journal Article